消息面上，基石药业公布，已在2025ESMO大会上首次发表CS2009(PD1/VEGF/CTLA-4三特异性抗体) 的I期临床研究初步数据，以及CS5001(ROR1抗体偶联药物ADC)的Ib期临床研究设计。 值得注意的是，根据香港联交所最新资料，GIC于10月13日披露再度增持基石药业，持股比例达到 6%。据悉，这是GIC在不到两个月内的第二次大举增持——此前8月18日，GIC曾大手笔增持基石药业 8040万股股份，耗资超6.3亿港元。 基石药业-B(02616)早盘涨超5%，截至发稿，涨7.41%，报7.39港元，成交额5465.48万港元。 ...

Core Viewpoint - 基石药业-B (02616) shares rose over 5% in early trading, reaching a peak increase of 7.41% at HKD 7.39, with a trading volume of HKD 54.65 million [1] Group 1: Clinical Research Developments - The company presented preliminary data from its Phase I clinical study of CS2009 (a PD1/VEGF/CTLA-4 trispecific antibody) at the 2025 ESMO conference [1] - Additionally, the design of the Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) was disclosed [1] Group 2: Shareholder Activity - GIC disclosed on October 13 that it has increased its stake in 基石药业 to 6% [1] - This marks GIC's second significant purchase of the company's shares in less than two months, having previously acquired 80.4 million shares on August 18 for over HKD 630 million [1]

基石药业-B(02616)发布公告，公司在2025年欧洲肿瘤内科学会(ESMO)年会上首次发表 CS2009(PD1/VEGF/CTLA-4三特异性抗体)的I期临床研究初步数据和CS5001(ROR1抗体偶联药物ADC) 的Ib期临床研究设计。 ...